EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The 2023 Impact of Inflammatory Bowel Disease in Canada: Mental Health and Inflammatory Bowel Disease

Lesley A Graff, Rose Geist, M Ellen Kuenzig iD, Eric I Benchimol iD, Gilaad G Kaplan iD, Joseph W Windsor iD, Alain Bitton, Stephanie Coward iD, Jennifer L Jones, Kate Lee, Sanjay K Murthy, Juan-Nicolás Peña-Sánchez iD und 19 weitere

Journal of the Canadian Association of Gastroenterology · 05.09.2023 · 6 (Supplement_2) · S64-S75

DOI: 10.1093/jcag/gwad012 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of the Canadian Association of Gastroenterology, online erschienen am 05.09.2023. Verfasst von Lesley A Graff und 30 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Health Psychology, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, …. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AbbVie Corporation, Janssen Canada, Pfizer Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Psychiatric disorders are 1.5 to 2 times more prevalent in persons with inflammatory bowel disease (IBD) than in the general population, with pooled prevalence estimates of 21% for clinical anxiety and 15% for depression. Rates are even higher when considering mental health symptoms, as nearly one-third of persons with IBD experience elevated anxiety symptoms and one-quarter experience depression symptoms. Rates of these symptoms were much higher during periods of disease activity, more common in women than men, and more common in Crohn’s disease than ulcerative colitis. There is robust evidence of the detrimental effects of comorbid depression and anxiety on the subsequent course of IBD based on longitudinal studies tracking outcomes over time. However, psychiatric disorders and IBD have bidirectional effects, with each affecting risk of the other. Elevated mental health concerns have been consistently associated with greater healthcare utilization and costs related to IBD. There is some signal that low resilience in adolescence could be a risk factor for developing IBD and that enhancing resilience may improve mental health and intestinal disease outcomes in IBD. Psychological therapies used to treat anxiety and depression occurring in the context of IBD have been shown to significantly improve the quality of life for persons with IBD and reduce anxiety and depression. There is less evidence in regard to the impact of psychotropic medications on mental health or disease outcomes in persons with IBD. There is consensus, however, that mental health must be addressed as part of comprehensive IBD care for children and adults.

Schlagwörter

Stichwörter der Autor:innen

AnxietyCrohn’s diseaseDepressionMental healthUlcerative colitis

Autor:innen und Institutionen

  • Department of Clinical Health Psychology, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
  • University of Manitoba IBD Clinical and Research Centre, Winnipeg, Manitoba, Canada.
  • Department of Psychiatry, The Hospital for Sick Children, University of Toronto, Toronto, Canada.
  • SickKids Inflammatory Bowel Disease Centre, Division of Gastroenterology, Hepatology, and Nutrition, The Hospital for Sick Children, Toronto, Ontario, Canada.
  • Child Health Evaluative Sciences, SickKids Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada.
  • ICES, Toronto, Ontario, Canada.

ORCID-Profile: M Ellen Kuenzig, Eric I Benchimol, Gilaad G Kaplan, Joseph W Windsor, Stephanie Coward, Juan-Nicolás Peña-Sánchez, Laura E Targownik, Noelle Rohatinsky, Charles N Bernstein

Förderung

  • AbbVie Corporation
  • Janssen Canada
  • Pfizer Canada
  • Bristol-Myers Squibb Canada
  • Amgen Canada
  • Takeda Foundation

Zitieren

APA

Graff, L. A., Geist, R., Kuenzig, M. E., Benchimol, E. I., Kaplan, G. G., Windsor, J. W., Bitton, A., Coward, S., Jones, J. L., Lee, K., Murthy, S. K., Peña-Sánchez, J. N., Targownik, L. E., Jannati, N., Jones May, T., Akhtar Sheekha, T., Davis, T., Weinstein, J., Dahlwi, G., …, & Bernstein, C. N. (2023). The 2023 Impact of Inflammatory Bowel Disease in Canada: Mental Health and Inflammatory Bowel Disease. Journal of the Canadian Association of Gastroenterology, 6(Supplement_2), S64-S75. https://doi.org/10.1093/jcag/gwad012

Vancouver

Graff LA, Geist R, Kuenzig ME, Benchimol EI, Kaplan GG, Windsor JW, et al. The 2023 Impact of Inflammatory Bowel Disease in Canada: Mental Health and Inflammatory Bowel Disease. Journal of the Canadian Association of Gastroenterology. 2023;6(Supplement_2):S64-S75. doi:10.1093/jcag/gwad012

BibTeX
@article{Graff2023,
  author = {Graff, Lesley A and Geist, Rose and Kuenzig, M Ellen and Benchimol, Eric I and Kaplan, Gilaad G and Windsor, Joseph W and Bitton, Alain and Coward, Stephanie and Jones, Jennifer L and Lee, Kate and Murthy, Sanjay K and Peña-Sánchez, Juan-Nicolás and Targownik, Laura E and Jannati, Nazanin and Jones May, Tyrel and Akhtar Sheekha, Tasbeen and Davis, Tal and Weinstein, Jake and Dahlwi, Ghaida and Im, James H B and Amankwah Osei, Jessica and Rohatinsky, Noelle and Ghandeharian, Sara and Goddard, Quinn and Gorospe, Julia and Gertsman, Shira and Louis, Michelle and Wagner, Richelle and Brass, Colten and Sanderson, Rhonda and Bernstein, Charles N},
  title = {The 2023 Impact of Inflammatory Bowel Disease in Canada: Mental Health and Inflammatory Bowel Disease},
  journal = {Journal of the Canadian Association of Gastroenterology},
  year = {2023},
  volume = {6},
  number = {Supplement_2},
  pages = {S64--S75},
  doi = {10.1093/jcag/gwad012}
}
Kostenlos starten →